Xintela : Newsletter no 6 2017

Read the newsletter by clicking here

Another year is coming to a close, and it has been an intensive one involving several important decisions and events. Construction of our own production facility for stem cells was one key decision that demonstrates that Xintela is advancing strongly in the field of regenerative medicine. The fact that Xintela has now taken this step is of paramount importance for the development of our stem cell products and heightens our appeal in discussions with existing and potential partners. All our projects continue to make excellent progress, and our position is considerably stronger than it was this time last year.

We recently announced that Xintela has signed a collaboration agreement with the leading Japanese cell therapy company CellSeed, which is developing a product for the treatment of cartilage damage in the knee joint. Initially, the collaboration will include the use of our integrin marker technology and quality control assay XACT for quality control of chondrocytes (cartilage cells) used in the company's product development. The collaboration agreement is very valuable since it both verifies the value of our technology and enables us to approach the Japanese market, which is world-leading in regenerative medicine.

During the year, Xintela took part in a large number of partnership conferences, including BIO International and BIO Europe, and met with numerous potential partners. In terms of the glioblastoma project, this resulted in discussions with several companies, now being conducted under confidentiality agreements, and moving forward in positive ways.

In this newsletter, we go into greater detail about the collaboration agreement with CellSeed. You can also read an analysis by Monocl Strategy Services which highlights the Japanese market as particularly interesting for Xintela. Moreover, Liselotte Theorell shares the progress being made on the production facility for stem cells.

To keep up the high pace of our projects in 2018, we have secured funding for a total of MSEK 17, before financial expenses, through a private placement and a loan. Our assessment is that this form of investment was the best option since we have now effectively improved the company's financial position while limiting dilution for the company's shareholders.

Finally, I would like to wish all our shareholders a very Merry Christmas and a Happy New Year as we look forward to a highly exciting 2018.
Evy Lundgren-Åkerlund,
CEO, Xintela AB